期刊文献+

毛细管气相色谱法测定普拉格雷中的有机溶剂残留量 被引量:1

Determination of residual organic solvents in prasugrel by capillary gas chromatography
下载PDF
导出
摘要 目的建立毛细管气相色谱法测定普拉格雷中的有机溶剂残留量。方法用DB624毛细管气相色谱柱,FID检测器,以丙酮为内标进行测定。结果乙醇、乙醚、二氯甲烷、乙酸乙酯的线性范围分别为50~800(r=0.999 5)、50~800(r=0.999 1)、6~96(r=0.999 4)、50~800 mg.L-1(r=0.999 6);乙醇、乙醚、二氯甲烷、乙酸乙酯的平均回收率分别为99.51%、98.97%、99.25%、99.32%;RSD为1.25%、1.14%、1.23%、1.05%(n=9)。结论本方法适用于普拉格雷中的有机溶剂残留量的测定。 Objective To develop a gas chromatography method for the determination of residual organic solvents in prasugrel.Methods The samples w ere injected into DB624 capillary column and analyzed w ith FID detector using acetone as the internal standard.Results The linear ranges of ethanol,ethyl ether,dichloromethane,ethyl acetate w ere 50-800 mg.L-1(r =0.999 5),50-800 mg.L-1(r =0.999 1),6-96 mg.L-1(r = 0.999 4),50-800 mg.L-1(r = 0.999 6) respectively.The recoveries were 99.51%,98.97%,99.25%,99.32%;RSD 1.25%,1.14%,1.23%,1.05%(n = 9) respectively.Conclusions The method is simple,accurate and sensitive w ith good reproducibility.It can be used for the determination of the residual organic solvents in prasugrel.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2013年第8期605-609,共5页 Journal of Shenyang Pharmaceutical University
关键词 普拉格雷 毛细管气相色谱法 有机溶剂残留量 prasugrel capillary residual organic solvents
  • 相关文献

参考文献8

  • 1荆亚萍,申东升,熊维,邓爵安.新一代血小板抑制剂——普拉格雷[J].国际药学研究杂志,2008,35(5):373-376. 被引量:22
  • 2陈航,闫亚非.抗血小板药物新进展[J].心血管病学进展,2009,30(1):105-109. 被引量:7
  • 3SEREBRUANY V L, MIDEI M G, MEILMAN H, et al. Platelet inhibition with prasugrel ( CS2747 ) com- pared with clopidogrel in patientsundergoing coronary stenting:the subset from the JUMBO study[ J]. Post- grad Med J,2006,82(968) :404 -410.
  • 4SUGIDACHI A, ASAI F, OGAWA T, et al. The in vi- vo pharmacologicalprofile of CS-747, a novel anti- platelet agent with platelet ADP receptor antagonist properties[ J ]. Br J Pharm aco1,2000,129 (7) : 1439 - 1446.
  • 5BRANDT J T, PAYNE C D, WIVIOTT S D, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation [ J ]. AmHeaaJ, 2007,153(1) :66. e9 -e16.
  • 6WALLENTIN L, VARENHORST C, JAMES S, et al. Prasugrel achievesgreater and faster P2Y12 receptor- mediated platelet inhibition than clopidogrel due to more efficient generation of its active me2tabolite in asp irin2treated patients with coronary artery disease EJ]. Eur Heart J,2007,29(1) :21 -30.
  • 7周海钧主译.药品注册的国际技术要求质量部分[M].北京:人民卫生出版社,2008:126-144.
  • 8朱杰,顾洪,殷学平.新药研究中残留溶剂控制问题的探讨[J].第二军医大学学报,2003,24(5):518-520. 被引量:5

二级参考文献56

  • 1Michos ED,Ardehali R,Blumenthal RS,et al. Aspirin and clopidogrel resistance [ J]. Mayo Clin Proc ,2006,81:518-526.
  • 2Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients[ J]. Thromb Res,1993,71:397-403.
  • 3Wang TH, Bhatt DL, Topoi EJ. Aspirin and clopidogrel resistance : an emerging clinical entity[ J]. Eur Heart J,2006,27:647-654
  • 4Laine L. Review article:gastrointestinal bleeding with low-dose aspirin--what's the risk [J] ? Aliment Pharmacol Ther,2006,24:897-908.
  • 5Savi P, Herbert JM. Clopidoga'el and ticlopidine:P2Y12 adenosine diphosphatereceptor antagonists for the prevention of atherothrombosis [ J ]. Semin Thromb Hemost,2005,31 : 174-183.
  • 6Muller I, Besta F, Schulz C, et al. Prevalence of elopidogrel non-responders among patients with stable angina peetoris scheduled for elective coronary stent placement [ J]. Thromb Haemost,2003,89 ( 5 ) :783 -787.
  • 7Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome p450 3A4 metabolic activity to the phenomenon of clopidogrel resistance[ J ]. Circulation ,2004,109 (2) :166-171.
  • 8Hechler B ,Zhang Y,Eckly A,et al. Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice [ J ]. J Thromb Haemost ,2003,1 ( 1 ) :155-163.
  • 9Thomas M, Kerry R J, Charter MK, et al. The phannacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects[J ]. Br J Clin Pharmacol, 1991, 32(2) :181-186.
  • 10Thomas M, Lumley P. Preliminary assessment of a novel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects [ J ]. Circulation, 1990, 81 : 153-158.

共引文献30

同被引文献5

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部